Liver Cancer Trial, Recruiting NCT04512846 Sponsor: Beijing 302 Hospital Condition: Liver Cancer
Back to Liver Cancer

Liver Cancer Trial, Recruiting

NCT04512846
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • A surgeon, radiologist, or oncologist has diagnosed the person with primary liver cancer (hepatocellular carcinoma, or HCC), either through imaging or a tissue sample, following international guidelines
  • The person has a single liver tumour that measures between 5 and 10 cm at its longest point
  • The person's liver function falls within a certain range, classified as Child-Pugh A or B (a measure of how well the liver is working — confirm with trial site)
  • The person has a general health score of 0 or 1 on the ECOG scale, meaning they are either fully active or able to carry out light activity (confirm with trial site)
  • The tumour is located more than 5 mm away from nearby organs such as the oesophagus, stomach, duodenum, and bowel
  • The person is not considered suitable for other treatments due to conditions such as heart disease, uncontrolled diabetes, or uncontrolled high blood pressure
  • The person has chosen not to pursue other treatments such as surgery to remove the tumour or a liver transplant
  • The person has blood counts meeting minimum levels: platelets at or above 50 × 10⁹/L and white blood cells at or above 1.5 × 10⁹/L
  • People with hepatitis B are being treated with adefovir or entecavir, OR people with hepatitis C have a negative HCV DNA test result

Who may not be able to join:

  • There is a blood clot caused by the tumour in a blood vessel (tumour thrombus)
  • The cancer has spread to nearby lymph nodes
  • The cancer has spread to areas outside the liver (extrahepatic metastasis)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +8613718681094

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Beijing 302 Hospital
Registry
ClinicalTrials.gov
Start date
1 August 2020
Est. completion
1 August 2023

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall survival time; Progression-free survival time; Local control time

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov